BOJI CRO(SZ:300404) Xin Lang Cai Jing·2025-09-09 03:17Core Viewpoint - Boji Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 23.08% but a recent decline in the short term, indicating potential volatility in the market [1][2]. Financial Performance - As of June 30, Boji Pharmaceutical reported a revenue of 361 million yuan, representing a year-on-year growth of 5.88%. However, the net profit attributable to shareholders decreased by 48.33% to approximately 15.57 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to approximately 27.76 million yuan, with 12.08 million yuan distributed over the past three years [3]. Stock Market Activity - On September 9, Boji Pharmaceutical's stock price fell by 2.01% to 10.73 yuan per share, with a trading volume of approximately 55.94 million yuan and a turnover rate of 1.84%. The total market capitalization stands at 4.14 billion yuan [1]. - The net outflow of main funds was approximately 1.31 million yuan, with large orders buying 7.36 million yuan (13.17%) and selling 8.68 million yuan (15.52%) [1]. Business Overview - Boji Pharmaceutical, established on September 29, 2002, and listed on April 24, 2015, is based in Guangzhou, Guangdong Province. The company specializes in providing preclinical research services, clinical research services, technology transfer services, and other consulting services related to new drug development [1]. - The revenue composition of Boji Pharmaceutical includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from other sources [1].